Friday, 21 Feb 2020

TissueGene Recognized During Maryland Commerce, State Departments' Week-Long Trade Mission To South Korea


TissueGene Recognized During Maryland Commerce, State Departments' Week-Long Trade Mission To South Korea
ROCKVILLE, Md., Sept. 14, 2017 : A trade and diplomatic mission to South Korea led by officials from the Maryland Department of Commerce and the Maryland Secretary of State's office concluded the evening of Friday, September 8, 2017, with a reception at the U.S. Ambassador to South Korea's residence in Seoul.

The reception featured a check presentation by First Lady Yumi Hogan and Maryland Deputy Secretary of Commerce Ben Wu to TissueGene, Inc., a Rockville-based advanced cell therapies company that has developed a first-in-class cell and gene therapy targeting osteoarthritis (OA) of the knee. The $750,000 grant from Maryland's Stem Cell Research Fund, administered by TEDCO, was announced earlier this year and will help the company to successfully conduct Phase III clinical trials in the United States for its product Invossa, a first-in-class cell and gene therapy targeting OA of the knee through a single intra-articular injection. TissueGene has designed its Phase III program to seek a disease-modifying osteoarthritis drug (DMOAD) designation for Invossa from the U.S. Food and Drug Administration (FDA)—potentially making Invossa the first therapy to receive a DMOAD label. In July 2017, Kolon Life Science, Inc., TissueGene's exclusive licensee for Asia, received South Korean MFDS marketing approval for Invossa-K Inj.

(PRN | 2 years ago)